257 related articles for article (PubMed ID: 29445836)
1. Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
Horne AM; Mihov B; Reid IR
Calcif Tissue Int; 2018 Jul; 103(1):55-61. PubMed ID: 29445836
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
3. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.
Lewiecki EM; Betah D; Humbert L; Libanati C; Oates M; Shi Y; Winzenrieth R; Ferrari S; Omura F
J Bone Miner Res; 2024 May; 39(4):473-483. PubMed ID: 38477808
[TBL] [Abstract][Full Text] [Related]
4. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
5. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
Lane J; Langdahl B; Stone M; Kurth A; Oates M; Timoshanko J; Wang Z; Libanati C; Cosman F
Osteoporos Int; 2024 Jul; 35(7):1195-1204. PubMed ID: 38573517
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
Miyauchi A; Hamaya E; Shimauchi J; Yoshinaga Y; Nishi K
J Bone Miner Metab; 2024 Jan; 42(1):77-89. PubMed ID: 38086988
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk following intermission of osteoporosis therapy.
Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
[TBL] [Abstract][Full Text] [Related]
8. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
Jeka S; Dokoupilová E; Kivitz A; Żuchowski P; Vogg B; Krivtsova N; Sekhar S; Banerjee S; Schwebig A; Poetzl J; Body JJ; Eastell R
J Bone Miner Res; 2024 Apr; 39(3):202-210. PubMed ID: 38477751
[TBL] [Abstract][Full Text] [Related]
9. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
Ramchand SK; Tsai JN; Lee H; Sassana-Khadka G; Jordan M; Ryan S; Leder BZ
Osteoporos Int; 2024 Feb; 35(2):255-263. PubMed ID: 37798320
[TBL] [Abstract][Full Text] [Related]
10. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years.
Reid IR; Horne AM; Mihov B; Bava U; Stewart A; Gamble GD
Lancet Diabetes Endocrinol; 2024 Apr; 12(4):247-256. PubMed ID: 38452783
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
[TBL] [Abstract][Full Text] [Related]
13. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
Hong N; Shin S; Lee S; Rhee Y
Osteoporos Int; 2023 Dec; 34(12):2059-2067. PubMed ID: 37596432
[TBL] [Abstract][Full Text] [Related]
14. Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty.
Nakura N; Hirakawa K; Takayanagi S; Mihara M
J Bone Miner Metab; 2023 Mar; 41(2):239-247. PubMed ID: 36745212
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
Lin X; Hu J; Zhou B; Wang X; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1873-1882. PubMed ID: 38181430
[TBL] [Abstract][Full Text] [Related]
16. Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study.
Brown J; Paggiosi MA; Rathbone E; Gregory W; Bertelli G; Din O; McCloskey E; Dodwell D; Cameron D; Eastell R; Coleman R
J Bone Miner Res; 2024 Mar; 39(1):8-16. PubMed ID: 38630878
[TBL] [Abstract][Full Text] [Related]
17. Treatment Sequence for Osteoporosis.
Cosman F; Langdahl B; Leder BZ
Endocr Pract; 2024 May; 30(5):490-496. PubMed ID: 38311211
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis.
Kamanda-Kosseh M; Shiau S; Agarwal S; Kondapalli A; Colon I; Kil N; Bucovsky M; Lappe JM; Stubby J; Shane E; Cohen A
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38605469
[TBL] [Abstract][Full Text] [Related]
19. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis.
Kumar S; Gild ML; McDonald MM; Kim AS; Clifton-Bligh RJ; Girgis CM
Osteoporos Int; 2024 Jun; ():. PubMed ID: 38839655
[TBL] [Abstract][Full Text] [Related]
20. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study.
Adami G; Pedrollo E; Rossini M; Fassio A; Braga V; Pasetto E; Pollastri F; Benini C; Viapiana O; Gatti D
JBMR Plus; 2024 Apr; 8(4):ziae016. PubMed ID: 38544922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]